A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal
- Conditions
- Renal Cell Carcinoma
- Registration Number
- NCT05168436
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this observational study is to determine patients' and professionals' preferences for the characteristics (attributes) of the treatment for Renal cell carcinoma (RCC) in Spain and Portugal.
- Detailed Description
This study uses a literature review, qualitative (focus groups) and quantitative methods (discrete-choice experiment, DCE) to determine renal cell carcinoma (RCC) participants and oncologists' preferences. In this clinical trial, the study team will develop a survey consisting of comparisons of hypothetical treatment profiles (scenarios). Scenarios are presented to participants, and each participant chooses the most preferable.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 105
Oncologists from Spain and Portugal will be identified by the promoter and invited to participate in the study in accordance with the inclusion criteria described below.
- The oncologist is currently working in a Spanish or Portuguese public hospital.
- The oncologist has at least 2 years of experience in the management of participants with Renal Cell Carcinoma (RCC).
- The oncologist has agreed to participate in the study.
Participants with a diagnosis of RCC will be identified and recruited by the Principal Investigators of the study, taking into account the inclusion criteria described below.
- The participant has been diagnosed with RCC for a minimum of 2 months before study inclusion.
- The participant has received or is currently receiving pharmacological treatment for RCC;
- The participant has provided the informed consent to participate in the study.
- The participant must be able to read, understand and complete the survey instrument according to the judgment of the responsible physician.
• Not applicable
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Utility: Renal cell carcinoma (RCC) participants' preferences At Baseline Utility (preference score) derived for a treatment alternative choice (scenario)
Utility: Oncologists' preferences At Baseline Utility (preference score) derived for a treatment alternative choice (scenario)
- Secondary Outcome Measures
Name Time Method Distribution of socio-demographic characteristics of RCC participants: Economic status (income) At Baseline Economic status, defined as Euros per month
Distribution of socio-demographic characteristics of Renal cell carcinoma (RCC) participants: Age At Baseline Mean age, defined as the difference in time between date of birth and baseline visit
Distribution of clinical characteristics of RCC participants: Time since RCC diagnosis At Baseline Mean time to diagnosis, defined as the differences in time between date of diagnosis and baseline visit
Distribution of socio-demographic characteristics of RCC participants: Working situation At Baseline Working situation, defined as working situation categories at baseline visit defined as full-time employed, part-time employed, self-employed, employed but on temporary sick leave due to RCC, permanent sick leave due to RCC, student, unemployed, retired, housework
Distribution of socio-demographic characteristics of RCC participants: Other costs derived from the visit to the hospital (parking, meals...) At Baseline Distribution of clinical characteristics of RCC participants: American Joint Committee on Cancer (AJCC) Staging At Baseline AJCC staging, defined as AJCC disease staging categories at baseline visit defined as Localized disease: Stages I and II; or advanced disease: Stages III and IV
Distribution of clinical characteristics of RCC participants: Charlson index At Baseline Charlson index, defined as Mean score according to Charlson comorbidity index
Distribution of clinical characteristics of RCC participants: Karnofsky Performance Scale Index At Baseline Karnofsky Performance Scale Index categories at baseline visit, defined as (0-100%); Lower score representing worst functional impairment
Distribution of clinical characteristics of RCC participants: Identification of previous pharmacological treatments received by the participant for the treatment of RCC At Baseline Previous drug treatment, defined as drug treatment categories at baseline visit
Distribution of socio-demographic characteristics of oncologists: Gender At Baseline Gender, defined as Gender categories at baseline visit, defined as female and male
Distribution of socio-demographic characteristics of oncologists: Years of experience in oncology At Baseline Years of experience in oncology, defined as Mean time of experience in oncology at baseline visit
Distribution of socio-demographic characteristics of RCC participants: Place of residence At Baseline Place of residence, defined as Province of residence categories at baseline visit
Distribution of socio-demographic characteristics of RCC participants: Gender At Baseline Gender, defined as Gender categories at baseline visit, defined as female and male
Distribution of socio-demographic characteristics of RCC participants: Education level At Baseline Education level, defined as education level categories at baseline visit, defined as primary education, secondary education, university education, third-level studies (masters, doctorate, etc.)
Distribution of clinical characteristics of RCC participants: Current drug treatment (if applicable) At Baseline Current drug treatment, defined as drug treatment categories at baseline visit
Distribution of socio-demographic characteristics of oncologists: Other types of cancer treated At Baseline Other types of cancer treated, defined as other cancers treated
Distribution of socio-demographic characteristics of oncologists: Level/ classification of hospital where employed At Baseline Hospital level or classification categories at baseline visit, defined as first, second, third, and fourth level
Distribution of socio-demographic characteristics of RCC participants: Transport to the hospital: means, duration and cost At Baseline Distribution of clinical characteristics of RCC participants: Description of previous pharmacological treatments received by the participant for the treatment of RCC At Baseline Previous drug treatment, defined as drug treatment categories at baseline visit
Distribution of socio-demographic characteristics of oncologists: Age At Baseline Mean age, defined as the difference in time between date of birth and baseline visit
Distribution of socio-demographic characteristics of oncologists: Province where employed At Baseline Province where employed, defined as Province categories at baseline visit
Distribution of socio-demographic characteristics of oncologists: Years of experience in RCC At Baseline Years of experience in RCC, defined as Mean time of experience in RCC at baseline visit
Distribution of socio-demographic characteristics of oncologists: Number of participants with RCC seen per year At Baseline Number of participants with RCC seen per year, defined as Mean time of participants with RCC seen per year
Trial Locations
- Locations (1)
Local Institution
🇪🇸Castellon de La Plana, Spain